Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen

Background: Nusinersen is an antisense-oligonucleotide (ASO) approved for treatment of 5q-spinal muscular atrophy (SMA). Since the drug cannot cross the blood-brain barrier (BBB), it must be administered into the cerebrospinal fluid (CSF) space repeatedly by lumbar puncture. However, little is known...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Front Neurol
Hauptverfasser: Wurster, Claudia D., Koch, Jan C., Cordts, Isabell, Dreyhaupt, Jens, Otto, Markus, Uzelac, Zeljko, Witzel, Simon, Winter, Benedikt, Kocak, Tugrul, Schocke, Michael, Weydt, Patrick, Wollinsky, Kurt, Ludolph, Albert C., Deschauer, Marcus, Lingor, Paul, Tumani, Hayrettin, Hermann, Andreas, Günther, René
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2019
Schlagworte:
Neurology
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6854024/
https://ncbi.nlm.nih.gov/pubmed/31787927
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2019.01179
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge